Batel Blechter PhD , Chao Agnes Hsiung PhD , Xiaoyu Wang MS , Haoyu Zhang PhD , Wei Jie Seow PhD , Jianxin Shi PhD , Nilanjan Chatterjee PhD , Hee Nam Kim MD, PhD , Maria Pik Wong MD , Yun-Chul Hong MD, PhD , Jason Y.Y. Wong PhD , Juncheng Dai PhD , H. Dean Hosgood PhD , Zhaoming Wang PhD , I-Shou Chang PhD , Jiyeon Choi PhD , Jiucun Wang PhD , Minsun Song PhD , Wei Hu PhD , Wei Zheng MD, PhD , Qing Lan MD, PhD
{"title":"Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report","authors":"Batel Blechter PhD , Chao Agnes Hsiung PhD , Xiaoyu Wang MS , Haoyu Zhang PhD , Wei Jie Seow PhD , Jianxin Shi PhD , Nilanjan Chatterjee PhD , Hee Nam Kim MD, PhD , Maria Pik Wong MD , Yun-Chul Hong MD, PhD , Jason Y.Y. Wong PhD , Juncheng Dai PhD , H. Dean Hosgood PhD , Zhaoming Wang PhD , I-Shou Chang PhD , Jiyeon Choi PhD , Jiucun Wang PhD , Minsun Song PhD , Wei Hu PhD , Wei Zheng MD, PhD , Qing Lan MD, PhD","doi":"10.1016/j.jtho.2024.11.019","DOIUrl":null,"url":null,"abstract":"<div><div>We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the <em>EGFR</em> gene in 998 East Asian never-smoking female LUAD cases (518 <em>EGFR</em>-positive; 480 <em>EGFR</em>-negative) and 4544 never-smoking controls using case-case and multinomial regression analyses. We found that the PRS was more strongly associated with <em>EGFR</em>-positive LUAD compared with <em>EGFR</em>-negative LUAD, where the association between the fourth quartile of the PRS and <em>EGFR</em>-positive LUAD (odds ratio = 8.63, 95% confidence interval: 5.67–13.14) was significantly higher than the association between the fourth quartile of the PRS with <em>EGFR</em>-negative LUAD (odds ratio = 3.50, 95% confidence interval: 2.44–5.00) (p-heterogeneity = 3.66 × 10<sup>−3</sup>). Our findings suggest that germline genetic susceptibility may be differentially associated with LUAD in never-smoking female East Asian patients depending on the cancer's mutation status, which may have important public health and clinical implications.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 521-530"},"PeriodicalIF":21.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086424024821","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the EGFR gene in 998 East Asian never-smoking female LUAD cases (518 EGFR-positive; 480 EGFR-negative) and 4544 never-smoking controls using case-case and multinomial regression analyses. We found that the PRS was more strongly associated with EGFR-positive LUAD compared with EGFR-negative LUAD, where the association between the fourth quartile of the PRS and EGFR-positive LUAD (odds ratio = 8.63, 95% confidence interval: 5.67–13.14) was significantly higher than the association between the fourth quartile of the PRS with EGFR-negative LUAD (odds ratio = 3.50, 95% confidence interval: 2.44–5.00) (p-heterogeneity = 3.66 × 10−3). Our findings suggest that germline genetic susceptibility may be differentially associated with LUAD in never-smoking female East Asian patients depending on the cancer's mutation status, which may have important public health and clinical implications.
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.